The association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States
- PMID: 38604474
- PMCID: PMC11402586
- DOI: 10.1016/j.japh.2024.102093
The association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States
Abstract
Background: Expanding access to naloxone through pharmacies is an important policy goal. Our objective was to characterize national county-level naloxone dispensing of chain versus independent pharmacies.
Methods: The primary exposure in our longitudinal analysis was the proportion of chain pharmacies in a county, identified through the U.S. Department of Homeland Security 2010 Infrastructure Foundation-Level Data. We defined counties as having "higher proportion" of chain pharmacies if at least 50% of pharmacies were large national chains. The primary outcome was quarter-year (2016Q1-2019Q2) rate of pharmacy naloxone claims per 100,000 persons from Symphony Health at the county level. We compared the naloxone dispensing rate between county types using 2-sample t tests. We estimated the association between county-level chain pharmacy proportion and rate of naloxone claims using a linear model with year-quarter fixed effects.
Results: Nearly one-third of counties (n = 946) were higher proportion. Higher proportion counties had a significantly higher rate of naloxone claims across the study period, in 4 of 6 urban-rural classifications, and in counties with and without naloxone access laws (NALs). The linear model confirmed that higher proportion counties had a significantly higher rate of naloxone claims, adjusting for urban-rural designation, income, population characteristics, opioid mortality rate, coprescribing laws, and NALs.
Conclusion: In this national study, we found an association between naloxone dispensing rates and the county-level proportion of chain (vs. independent) pharmacies. Incentivizing naloxone dispensing through educational, regulatory, or legal efforts may improve naloxone availability and dispensing rates-particularly in counties with proportionately high numbers of independent pharmacies.
Copyright © 2024 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The authors declare no relevant conflicts of interest or financial relationships.
Figures
Similar articles
-
Implementation of Medication Disposal Programs and Availability of Same-Day Naloxone at Community Pharmacies: Protocol for a Secret Shopper Caller Approach.JMIR Res Protoc. 2025 Jun 10;14:e64344. doi: 10.2196/64344. JMIR Res Protoc. 2025. PMID: 40493386 Free PMC article.
-
Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1725-1740. doi: 10.1016/j.japh.2022.07.008. Epub 2022 Jul 31. J Am Pharm Assoc (2003). 2022. PMID: 35989151
-
Community-Originated Research to Identify Access Gaps in Over-the-Counter Naloxone Availability in Connecticut Pharmacies.Harm Reduct J. 2025 Jul 14;22(1):119. doi: 10.1186/s12954-025-01268-y. Harm Reduct J. 2025. PMID: 40660265 Free PMC article.
-
Naloxone Availability and Cost After Transition to an Over-the-Counter Product.JAMA Health Forum. 2024 Jul 5;5(7):e241920. doi: 10.1001/jamahealthforum.2024.1920. JAMA Health Forum. 2024. PMID: 39058509 Free PMC article.
-
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.Cochrane Database Syst Rev. 2018 Jun 5;6(6):CD006332. doi: 10.1002/14651858.CD006332.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2022 Sep 15;9:CD006332. doi: 10.1002/14651858.CD006332.pub4. PMID: 29869799 Free PMC article. Updated.
Cited by
-
Naloxone training programs in corporately-owned versus independently-owned Alabama community pharmacies: A pilot cross-sectional survey.Drug Alcohol Depend Rep. 2025 Mar 28;15:100326. doi: 10.1016/j.dadr.2025.100326. eCollection 2025 Jun. Drug Alcohol Depend Rep. 2025. PMID: 40247910 Free PMC article.
-
Transforming Opioid Overdose Prevention in the United States: Leveraging FDA's Narcan Approval to Foster a Culture of Health.Risk Manag Healthc Policy. 2025 Jun 14;18:1935-1946. doi: 10.2147/RMHP.S521720. eCollection 2025. Risk Manag Healthc Policy. 2025. PMID: 40535536 Free PMC article.
References
-
- Drug Overdose Death Rates. National Institute on Drug Abuse. Published February 9, 2023. Accessed May 10, 2023. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
-
- Harm Reduction. Published February 15, 2022. Accessed March 30, 2022. https://www.samhsa.gov/find-help/harm-reduction
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources